Alimera Sciences (ALIM) Earning Somewhat Positive Media Coverage, Study Finds

News articles about Alimera Sciences (NASDAQ:ALIM) have been trending somewhat positive on Sunday, Accern reports. The research group rates the sentiment of press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Alimera Sciences earned a news impact score of 0.18 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 47.6335064670026 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

ALIM traded down $0.01 during midday trading on Friday, reaching $1.03. 105,608 shares of the company were exchanged, compared to its average volume of 170,708. The company has a debt-to-equity ratio of -0.64, a quick ratio of 3.91 and a current ratio of 4.07. The firm has a market capitalization of $72.09, a P/E ratio of -3.55 and a beta of 1.58. Alimera Sciences has a one year low of $1.01 and a one year high of $1.70.

Alimera Sciences (NASDAQ:ALIM) last issued its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.07). The business had revenue of $9.14 million during the quarter, compared to analysts’ expectations of $9.60 million. equities analysts forecast that Alimera Sciences will post -0.06 earnings per share for the current year.

A number of research analysts recently weighed in on the company. HC Wainwright reaffirmed a “buy” rating and set a $5.00 price target on shares of Alimera Sciences in a research note on Monday, January 22nd. ValuEngine downgraded Alimera Sciences from a “sell” rating to a “strong sell” rating in a research note on Sunday, December 3rd. Finally, Zacks Investment Research raised Alimera Sciences from a “hold” rating to a “buy” rating and set a $1.25 price target on the stock in a research note on Thursday, March 22nd. One research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $3.31.

In other news, CEO C. Daniel Myers sold 52,900 shares of the company’s stock in a transaction that occurred on Wednesday, January 17th. The stock was sold at an average price of $1.23, for a total value of $65,067.00. Following the completion of the transaction, the chief executive officer now directly owns 154,411 shares of the company’s stock, valued at $189,925.53. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, SVP Philip Ashman sold 25,500 shares of the company’s stock in a transaction that occurred on Wednesday, January 17th. The shares were sold at an average price of $1.23, for a total value of $31,365.00. Following the completion of the transaction, the senior vice president now directly owns 38,250 shares of the company’s stock, valued at $47,047.50. The disclosure for this sale can be found here. Insiders have sold a total of 184,704 shares of company stock valued at $224,432 over the last three months. Corporate insiders own 14.70% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was originally reported by BBNS and is the sole property of of BBNS. If you are reading this article on another site, it was illegally stolen and reposted in violation of US and international copyright law. The original version of this article can be read at https://baseballnewssource.com/2018/04/02/alimera-sciences-alim-given-media-impact-score-of-0-18/2001348.html.

Alimera Sciences Company Profile

Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.

Insider Buying and Selling by Quarter for Alimera Sciences (NASDAQ:ALIM)

Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

 




Latest News

Ji-Man Choi Receives Another Chance in Milwaukee
Ji-Man Choi Receives Another Chance in Milwaukee
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Strikeouts Once Again Plaguing Cubs
Strikeouts Once Again Plaguing Cubs
Atlanta Braves: A Mix of Young and Old
Atlanta Braves: A Mix of Young and Old
Major League Baseball is Back and Astros Favored to Repeat
Major League Baseball is Back and Astros Favored to Repeat
Jim Kaat: Baseball Would Be Helped by Shortening Game to Seven Innings
Jim Kaat: Baseball Would Be Helped by Shortening Game to Seven Innings


Leave a Reply

 
© 2006-2018 BBNS.